Orange Bagasse Pellets as a Carbon Source for Biobutanol Production.

Due to the environmental concerns, the conversion of lignocellulosic waste can be the key to produce bioproducts and biofuels such as butanol. This study aimed to present and evaluate orange bagasse pellets (OBP) as a carbon source to produce butan-1-ol production via ABE fermentation using Clostridium beijerinckii. These bagasse pellets were characterized, holocellulose (18.99%), alfacellulose (5.37%), hemicellulose (13.62%), lignin (6.16%), pectin (7.21%), protein (3.14%), and was tested under three different pretreatments, which were the following: (a) ultrasound, (b) autohydrolysis, and (c) acid-diluted hydrolysis followed by enzymatic hydrolysis to verify an amount of fermentable total reducing sugars. ANOVA was used and pretreatments followed by enzymatic hydrolysis do not enhance a significant amount of available sugars compared to raw bagasse. The ABE fermentation was carried out in batch reactors at 37 °C under agitation of 160 rpm and anaerobic conditions, using OBP without treatment followed by enzymatic hydrolysis. Using a non-mutant microorganism, the fermentation achieved butyric acid yields of 3762.68 mg L-1 for control and 2488.82 mg L-1 for OBP and the butanol production was 63.86 mg L-1 and 196.80 mg L-1 for OBP and the control (glucose) assay, respectively. The results of this solvent's production have shown that OBP has the potential for ABE fermentation and a promising feedstock.

Promising nanotherapy in treating leishmaniasis.

Leishmaniases are infectious diseases caused by an intracellular protozoan in humans by 20 different species of Leishmania among more than 53 species. There are at least twelve million cases of infections worldwide and three hundred and fifty million people are at risk in at least 98 developing countries in Africa, South-East Asia, and the Americas. Only Brazil presented high burden for both visceral leishmaniasis (VL) and cutaneous (CL). Chemotherapy is the main means of dealing with this infection. Nevertheless, only a few effective drugs are available, and each has a particular disadvantage; toxicity and long-term regimens compromise most chemotherapeutic options, which decreases patient compliance and adherence to the treatment and consequently the emergence of drug-resistant strains. Nano drug delivery systems (NanoDDS) can direct antileishmanial drug substances for intracellular localization in macrophage-rich organs such as bone marrow, liver, and spleen. This strategy can improve the therapeutic efficacy and reduce the toxic effects of several antileishmanial drug substances. This review is an effort to comprehensively compile recent findings, with the aim of advancing understanding of the importance of nanotechnology for treating leishmaniases.